DDInter1340 DDInter413
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997.
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Clopidogrel
Omeprazole {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Clopidogrel
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clopidogrel
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clopidogrel
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Ticlopidine
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Omeprazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) regulates {v} (Gene) SQRDL
SQRDL {u} (Gene) is upregulated by {v} (Compound) Clopidogrel
Omeprazole {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clopidogrel
Omeprazole {u} (Compound) causes {v} (Side Effect) Anaphylactic shock
Anaphylactic shock {u} (Side Effect) is caused by {v} (Compound) Ticlopidine
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Omeprazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Clopidogrel (Compound)
Omeprazole (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Clopidogrel (Compound)
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may lead to a major life threatening interaction when taken with Clopidogrel
Omeprazole (Compound) resembles Esomeprazole (Compound) and Es
Omeprazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ticlopidine (Compound) and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Omeprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates SQRDL (Gene) and SQRDL (Gene) is upregulated by Clopidogrel (Compound)
Omeprazole (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Fluvastatin (Compound) and Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Clopidogrel
Omeprazole (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Ticlopidine (Compound) and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel